Skip to content
★ Sign in to follow
MH

Michael Häggman

Board Director
Director
Prostatype Genomics AB
Insider activity · 24 months2 buys0 salesCumulative net flow
Total declarations
9
Company
1
▲ Purchases (4 ops.)
€59k
▼ Sales (0 ops.)
—

Latest filing published 25 Sept 2026 for Prostatype Genomics AB, €6,306.

Filing timeline

BuySale
Michael Häggman

Insider track record

Disclosed buys
4
Disclosed sells
0
Signal history

No signal scores available.

Closed purchases

Market purchases
4

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Michael Häggman: trading record in brief

Michael Häggman is a declared insider of Prostatype Genomics AB (board member), with filings sourced from Finansinspektionen. Over a trading history stretching from 11 May 2023 to 15 September 2026, the count stands at 9 filings.

The open-market record is one-sided, with 4 purchases worth €59k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants. In 2026 alone, the filings show 1 purchase and no sales.

A typical purchase (the median) is worth €15k.

The newest entry dates from 25 September 2026: a transaction of €6,306, in Prostatype Genomics AB. The last insider purchase was made public on 5 August 2026, 94 days ago. Typically, a trade is published a median of 6 days after it takes place. The legal deadline for notifying a trade is three business days (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Michael Häggman

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations9 total
  • ●
    StyrelseledamotExecutivesProstatype Genomics AB
    71,500 SEK19FI-SE
    715,000 shares@ SEK 0.100.37% mcap9.4% of flowInterimsaktieISIN SE0030262895FI:csv-ec94f3ff08c32cb84cf5
  • ▲
    StyrelseledamotExecutivesProstatype Genomics AB
    286,000 SEK0FI-SE
    357,500 shares@ SEK 0.8042.6% of flowBTU (betald tecknad unit)ISIN SE0018245425FI:csv-90d3564b943842143195
    Canonical exit: 3 Nov 2026 (T+90)
  • ◆
    StyrelseledamotExecutivesProstatype Genomics AB
    84,332 SEK0FI-SE
    162,177 shares@ SEK 0.5212.6% of flowBTA (betald tecknad aktie)ISIN SE0023261532FI:A003S822-1
  • ▲
    StyrelseledamotExecutivesProstatype Genomics AB
    228,360 SEK0FI-SE
    57,090 shares@ SEK 4.0034.3% of flowBTU (betald tecknad unit)ISIN SE0024990071FI:A003P638-1
    Canonical exit: 3 Sept 2025 (T+90)
  • ●
    StyrelseledamotExecutivesProstatype Genomics AB
    77,480 SEK0FI-SE
    13,000 shares@ SEK 5.96InlösenrättISIN SE0023261532FI:csv-f74f79b5402bd1a12130
  • ◆
    StyrelseledamotExecutivesProstatype Genomics AB
    0FI-SE
    13,000,000 shares0TeckningsoptionISIN SE0022574554FI:csv-27cb374640ac934c214b
  • ●
    StyrelseledamotExecutivesProstatype Genomics AB
    313,032 SEK0FI-SE
    782,579 shares@ SEK 0.4012.6% of flowBTU (betald tecknad unit)ISIN SE0018245425FI:csv-31670a01c136c455fd47
  • ▲
    StyrelseledamotExecutivesProstatype Genomics AB
    50,000 SEK0FI-SE
    200,000 shares@ SEK 0.252.0% of flowBTA (betald tecknad aktie)ISIN SE0020179430FI:csv-91251229de0f5d197f6a
    Canonical exit: 14 Aug 2023 (T+90)
  • ▲
    StyrelseledamotExecutivesProstatype Genomics AB
    92,696 SEK0FI-SE
    370,782 shares@ SEK 0.253.7% of flowBTA (betald tecknad aktie)ISIN SE0020179430FI:csv-13e05db00f54da3f6c3c
    Canonical exit: 9 Aug 2023 (T+90)

9 of 9 declarations